Knoll Pharma: Buyback on hold - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Knoll Pharma: Buyback on hold

Jun 18, 2002

Knoll Pharmaceuticals, (now a subsidiary of Abott Labs) has registered a marginal decline in sales for 1QFY03. However, a sharp rise in operating margins helped the company register a 53% rise in profits. Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market.

(Rs m)1QFY021QFY03% Change
Sales 813 802-1.4%
Other Income 25 4892.0%
Expenditure 701 643-8.2%
Operating Profit (EBDIT) 112 159 41.5%
Operating Profit Margin (%)13.8%19.8% 
Interest 1 0-70.0%
Depreciation 11 1540.0%
Profit before Tax 125 191 52.6%
Extraordinary Income   
Tax 33 5051.5%
Profit after Tax/(Loss) 92 141 53.0%
Net profit margin (%)11.3%17.6% 
No. of Shares (eoy) (m) 16.2 16.2 
Diluted Earnings per share*22.734.8 
P/E (at current price)13.38.7 
(*- annualised)   

The rise in operating margins is on account of two reasons. The current year's financials received a boost on account of upward revision in prices of four formulations of insulin by NPPA last September. Secondly, last year, the company profits dipped following a cut in Ibuprofen prices by NPPA. Ibuprofen is a bulk drug used in pain management segment. As Knoll Pharma is a market leader in Ibuprofen market, the price cut had a severe impact on the company's financials in 1QFY02.

Knoll Pharmaceuticals Ltd had recently announced the buyback of 919,000 fully paid up equity shares from the existing shareholders through a tender offer at a price of Rs 350 per share. This represents around 14% of the free float of the company. However, pending certain regulatory approvals from SEBI, the buyback stands annulled for the time being. The latest available shareholding pattern is as follows:

The stock is currently trading at a P/e multiple of 9x FY02 earnings, a 16% discount to its proposed open offer price. The stock trades at considerable discount to its peers. Knoll Pharma’s financials are expected to look up in the short term, mirroring the Insulin price revision. However, in the long term competition is expected to set in quickly, threatening the leadership position of the company. Lot of domestic players like Glenmark, Wockhardt and Shanta Bio-tech already have clear plans to enter the insulin market. Considering the size and price of the proposed buyback offer, the stock price is expected to remain range bound in the near term.

Equitymaster requests your view! Post a comment on "Knoll Pharma: Buyback on hold". Click here!


More Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Jun 18, 2021 (Close)


  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks